cancer Archives - Page 2 of 3

Feature

PharmaCyte’s Cell-in-a-Box encapsulation technology targeting cancer, diabetes

PharmaCyte Biotech (OTCQB:PMCB) is developing cellular therapies for its lead pancreatic cancer program and for diabetes that are based on a proprietary cellulose-based live cell encapsulation technology known as a Cell...

July 23, 2019

Developments

BeyondSpring prices $35-million equity offering

BeyondSpring (NASDAQ:BYSI) priced a public offering of 2,058,825 ordinary shares at $17 apiece for expected gross proceeds of $35-million. The offering was led by Decheng Capital. The underwriter has a 30-day option to...

July 17, 2019

Executive Moves

Soricimed taps industry veteran, Robert Bruce, as CEO

Closely-held Soricimed Biopharma appointed Robert Bruce as CEO, effective immediately, succeeding Paul Gunn, who continues as president. “Soricimed is taking an important step forward at this time and I am excited to...

July 17, 2019

Developments

Imagin Medical updates i/Blue’s functional unit development

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) provided an update on its progress towards verifying the i/Blue imaging system’s functional prototype. The company has integrated the i/Blue...

July 15, 2019

Executive Moves

PharmaCyte appoints cellular expert, David Judd, to medical and SAB

David Judd PharmaCyte Biotech (OTCQB: PMCB) appointed David Judd to its medical and scientific advisory board. Mr. Judd has had over 30 years of experience in the research and development of cell culture materials and...

July 15, 2019

Feature

Rgenix’s discovery platform identifying novel RNA-regulated cancer targets

By Len Zehr Closely-held Rgenix has identified novel cancer targets regulated by microRNA pathways, which are key drivers of cancer progression, and developed first-in-class treatments that have the potential to...

October 16, 2018

Feature

Nanobiotix pioneering nanomedicine in new paradigm against cancer

By Len Zehrs France’s Nanobiotix (Euronext:NANO) is hoping to change the paradigm for cancer treatment with a single nanomedicine applicable across oncology for millions of patients. “What differentiates us is that we...

May 15, 2018

Feature

Contextual Genomics detecting genetic mutations in cancer

By Len Zehr Closely-held Contextual Genomics is giving oncologists a leg up to enhance cancer care with its new Find-It molecular test to detect genetic mutations in cancer patients. “We deliver solutions through our...

August 15, 2017

Feature

Lion Biotechnologies spearheading TILs in solid tumors

By Len Zehr Lion Biotechnologies (NASDAQ:LBIO) is establishing a leading position in immuno-oncology through its tumor-infiltrating lymphocyte (TIL) technology to deliver personalized oncology therapies to patients with...

April 11, 2017

Feature

Triumvira targeting cancer with customized T cells

By Len Zehr Closely-held Triumvira Immunologics is developing a novel platform to engineer the immune system’s T cells to attack cancer using proprietary T Cell-Antigen Couplers (TACs). “TACs were designed to use the...

July 26, 2016

Tag - cancer

PharmaCyte’s Cell-in-a-Box encapsulation technology targeting cancer, diabetes

BeyondSpring prices $35-million equity offering

Soricimed taps industry veteran, Robert Bruce, as CEO

Imagin Medical updates i/Blue’s functional unit development

PharmaCyte appoints cellular expert, David Judd, to medical and SAB

Rgenix’s discovery platform identifying novel RNA-regulated cancer targets

Nanobiotix pioneering nanomedicine in new paradigm against cancer

Contextual Genomics detecting genetic mutations in cancer

Lion Biotechnologies spearheading TILs in solid tumors

Triumvira targeting cancer with customized T cells

General

More